Table 3. Lancinating Pain Score Changes According to Baseline Antidiabetic Regimen, HbA_1c Level, and Serum Homocysteine Level by Study Group.

Score Change From Baseline	By Month 6			By Month 12
	Placebo (n = 150)	Tocotrienols (n = 150)	P Value	Placebo (n = 150)	Tocotrienols (n = 150)	P Value
Baseline HbA1c
HBA1c ≤8.0%	−0.4 (1.6)	−0.4 (1.2)	.97	−0.4 (1.7)	−0.6 (1.1)	.71
HBA1c >8.0%	−0.1 (1.3)	−0.7 (1.4)	.008	−0.2 (1.2)	−0.7 (1.4)	.03
Baseline homocysteinea
A subgroup (<2.03 mg/L)	−0.2 (1.5)	−0.7 (1.5)	.01	−0.3 (1.5)	−0.9 (1.3)	.008
H subgroup (≥2.03 mg/L)	−0.4 (1.4)	−0.3 (1.0)	.71	−0.4 (1.1)	−0.2 (1.2)	.39

Abbreviation: HbA_1c, hemoglobin A_1c.

SI conversion factors: To convert homocysteine to micromoles per liter, multiply by 7.397; folate to nanomoles per liter, multiply by 2.266.

^aIn the stratified analysis, participants were further categorized to an A subgroup (<2.03 mg/L) and an H subgroup (≥2.03 mg/L) at baseline.